Diagnosis Value of Aberrantly Expressed MicroRNA Profiles in Lung Squamous Cell Carcinoma: a Study Based on the Cancer Genome Atlas

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2017 Dec 6

PMID 29204322

Citations 5

Authors

Sheng Yang

Jing Sui

Geyu Liang

Affiliations

Soon will be listed here.

Abstract

Background: Lung cancer is considered as one of the most frequent and deadly cancers with high mortality all around the world. It is critical to find new biomarkers for early diagnosis of lung cancer, especially lung squamous cell carcinoma (LUSC). The Cancer Genome Atlas (TCGA) is a database which provides both cancer and clinical information. This study is a comprehensive analysis of a novel diagnostic biomarker for LUSC, based on TCGA.

Methods And Results: The present study investigated LUSC-specific key microRNAs (miRNAs) from large-scale samples in TCGA. According to exclusion criteria and inclusion criteria, the expression profiles of miRNAs with related clinical information of 332 LUSC patients were obtained. Most aberrantly expressed miRNAs were identified between tumor and normal samples. Forty-two LUSC-specific intersection miRNAs (fold change >2, < 0.05) were obtained by an integrative computational method, among them six miRNAs were found to be aberrantly expressed concerning characteristics of patients (gender, lymphatic metastasis, patient outcome assessment) through Student -test. Five miRNAs correlated with overall survival (log-rank < 0.05) were obtained through the univariate Cox proportional hazards regression model and Mantel-Haenszel test. Then, five miRNAs were randomly selected to validate the expression in 47 LUSC patient tissues using quantitative real-time polymerase chain reaction. The results showed that the test findings were consistent with the TCGA findings. Also, the diagnostic value of the specific key miRNAs was determined by areas under receiver operating characteristic curves. Finally, 577 interaction mRNAs as the targets of 42 LUSC-specific intersection miRNAs were selected for further bioinformatics analysis.

Conclusion: This study indicates that this novel microRNA expression signature may be a useful biomarker of the diagnosis for LUSC patients, based on bioinformatics analysis.

Citing Articles

MiR-497-5p down-regulates CDCA4 to restrains lung squamous cell carcinoma progression.

Hu J, Xiang X, Guan W, Lou W, He J, Chen J J Cardiothorac Surg. 2021; 16(1):330.

PMID: 34772428 PMC: 8588708. DOI: 10.1186/s13019-021-01698-2.

Prediction of clusters of miRNA binding sites in mRNA candidate genes of breast cancer subtypes.

Aisina D, Niyazova R, Atambayeva S, Ivashchenko A PeerJ. 2019; 7:e8049.

PMID: 31741798 PMC: 6858813. DOI: 10.7717/peerj.8049.

MiR-223-3p functions as a tumor suppressor in lung squamous cell carcinoma by miR-223-3p-mutant p53 regulatory feedback loop.

Luo P, Wang Q, Ye Y, Zhang J, Lu D, Cheng L J Exp Clin Cancer Res. 2019; 38(1):74.

PMID: 30755230 PMC: 6373043. DOI: 10.1186/s13046-019-1079-1.

MicroRNA-705 regulates the differentiation of mouse mandible bone marrow mesenchymal stem cells.

Yang X, Yang K, An Y, Wang L, Luo G, Hu X PeerJ. 2019; 7:e6279.

PMID: 30648022 PMC: 6330203. DOI: 10.7717/peerj.6279.

Molecular characterization of papillary thyroid carcinoma: a potential three-lncRNA prognostic signature.

You X, Yang S, Sui J, Wu W, Liu T, Xu S Cancer Manag Res. 2018; 10:4297-4310.

PMID: 30349364 PMC: 6183593. DOI: 10.2147/CMAR.S174874.

References

Huang T, Yang J, Cai Y . Novel candidate key drivers in the integrative network of genes, microRNAs, methylations, and copy number variations in squamous cell lung carcinoma. Biomed Res Int. 2015; 2015:358125. PMC: 4352729. DOI: 10.1155/2015/358125. View

Wiedl T, Arni S, Roschitzki B, Grossmann J, Collaud S, Soltermann A . Activity-based proteomics: identification of ABHD11 and ESD activities as potential biomarkers for human lung adenocarcinoma. J Proteomics. 2011; 74(10):1884-94. DOI: 10.1016/j.jprot.2011.04.030. View

Hsu N, Lee H, Yen Y, Cheng Y . Human papillomavirus and non-small cell lung cancer. Thorac Cancer. 2017; 4(4):345-353. DOI: 10.1111/1759-7714.12030. View

Wang L, Zhu M, Ren A, Wu H, Han W, Tan R . A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. PLoS One. 2014; 9(5):e96472. PMC: 4015980. DOI: 10.1371/journal.pone.0096472. View

Xu G, Chen J, Pan Q, Huang K, Pan J, Zhang W . Long noncoding RNA expression profiles of lung adenocarcinoma ascertained by microarray analysis. PLoS One. 2014; 9(8):e104044. PMC: 4121291. DOI: 10.1371/journal.pone.0104044. View

Zhu J, Zeng Y, Xu C, Qin H, Lei Z, Shen D . Expression profile analysis of microRNAs and downregulated miR-486-5p and miR-30a-5p in non-small cell lung cancer. Oncol Rep. 2015; 34(4):1779-86. DOI: 10.3892/or.2015.4141. View

Chang Y, Kuo W, Hung J, Lee C, Lee Y, Chang Y . Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing. Mol Cancer. 2015; 14:36. PMC: 4351690. DOI: 10.1186/s12943-015-0301-9. View

Sadaf A, Zeshan B, Wang Z, Zhang R, Xu S, Wang C . Toxicity evaluation of hydrophilic CdTe quantum dots and CdTe@SiO2 nanoparticles in mice. J Nanosci Nanotechnol. 2013; 12(11):8287-92. DOI: 10.1166/jnn.2012.6667. View

Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, Rom W . microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol. 2013; 8(9):1156-62. PMC: 4123222. DOI: 10.1097/JTO.0b013e318299ac32. View

10.

Zhou W, Ding Q, Pan H, Wu N, Liang M, Huang Y . Risk of breast cancer and family history of other cancers in first-degree relatives in Chinese women: a case control study. BMC Cancer. 2014; 14:662. PMC: 4168164. DOI: 10.1186/1471-2407-14-662. View

11.

Wang Y, Zhao H, Gao X, Wei F, Zhang X, Su Y . Identification of a three-miRNA signature as a blood-borne diagnostic marker for early diagnosis of lung adenocarcinoma. Oncotarget. 2016; 7(18):26070-86. PMC: 5041965. DOI: 10.18632/oncotarget.8429. View

12.

Torres-Duran M, Ruano-Ravina A, Parente-Lamelas I, Leiro-Fernandez V, Abal-Arca J, Montero-Martinez C . Residential radon and lung cancer characteristics in never smokers. Int J Radiat Biol. 2015; 91(8):605-10. DOI: 10.3109/09553002.2015.1047985. View

13.

Hiroki E, Akahira J, Suzuki F, Nagase S, Ito K, Suzuki T . Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci. 2009; 101(1):241-9. PMC: 11159282. DOI: 10.1111/j.1349-7006.2009.01385.x. View

14.

Peng L, Bian X, Li D, Xu C, Wang G, Xia Q . Large-scale RNA-Seq Transcriptome Analysis of 4043 Cancers and 548 Normal Tissue Controls across 12 TCGA Cancer Types. Sci Rep. 2015; 5:13413. PMC: 4544034. DOI: 10.1038/srep13413. View

15.

Pu W, Geng X, Chen S, Tan L, Tan Y, Wang A . Aberrant methylation of can be a diagnostic biomarker for lung adenocarcinoma. J Cancer. 2016; 7(15):2280-2289. PMC: 5166538. DOI: 10.7150/jca.15758. View

16.

Yang P . Lung cancer in never smokers. Semin Respir Crit Care Med. 2011; 32(1):10-21. PMC: 3404817. DOI: 10.1055/s-0031-1272865. View

17.

Sun F, Yang X, Jin Y, Chen L, Wang L, Shi M . Bioinformatics analyses of the differences between lung adenocarcinoma and squamous cell carcinoma using The Cancer Genome Atlas expression data. Mol Med Rep. 2017; 16(1):609-616. PMC: 5482124. DOI: 10.3892/mmr.2017.6629. View

18.

Torre L, Siegel R, Jemal A . Lung Cancer Statistics. Adv Exp Med Biol. 2015; 893:1-19. DOI: 10.1007/978-3-319-24223-1_1. View

19.

Su Y, Ni Z, Wang G, Cui J, Wei C, Wang J . Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p. Int Immunopharmacol. 2012; 13(4):468-75. PMC: 3389336. DOI: 10.1016/j.intimp.2012.05.016. View

20.

Remon J, Alvarez-Berdugo D, Majem M, Moran T, Reguart N, Lianes P . miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers. Clin Transl Oncol. 2015; 18(2):153-9. DOI: 10.1007/s12094-015-1347-2. View